Valicare GmbH extends GxP expertise

Valicare GmbH, a wholly owned subsidiary of Syntegon, now offers additional services along the entire product life cycle of pharmaceutically and biotechnologically produced drugs. A new focus is on consulting services for the transition of products from the development phase to the GMP compliant manufacturing of investigational medicinal products. These services are complemented by the presentation and assessment of market-specific requirements, investigational drug management and the necessary regulatory interactions.

Addition to the team

To underline the extension of the service portfolio, Valicare has recruited Dr. Christin Erbach to join the expert team of engineers and scientists as a Senior GMP Consultant. Dr. Erbach has more than ten years of clinical service experience along with deep knowledge in quality management and legal pharmaceutical requirements. She also successfully supported pharmaceutical businesses during their establishment phase. “Her specialized knowledge in the area of clinical services combined with her legal background is an outstanding addition to Valicare’s consultancy business,” says Dr. Hans-Georg Eckert, site manager of Valicare in Frankfurt. “She will strengthen our competencies regarding the first GMP steps and the legal requirements for clinical products, addressing special needs for each development stage. This way, we are able to extend our approach of accompanying products along their complete life cycle.”

Valicare is significantly expanding its GxP and consultancy services for the pharma, biotech and ATMP industries to fulfill individual demands regarding products and projects from development to market release. As far as ATMPs are concerned, the company already supports customers in meeting regulatory requirements for more and more individual therapies and minimizing associated risks. Valicare also offers complete solutions for the production of ATMPs as well as consulting and supporting services, right through to the production of the first investigational medicinal products.